TTK Healthcare's Q4 results show revenue growth to ₹1.90 billion, up 5.56% year-over-year. However, profitability declined with EBITDA falling to ₹120.00 million and net profit decreasing to ₹161.00 million. Despite challenges, the company declared a dividend of ₹10.00 per share.
02May 25
TTK Healthcare Faces Setback as USAID Cancels Condom Procurement Agreement
TTK Healthcare announced the cancellation of its agreement with Chemonics due to USAID's decision to stop condom procurement from the company. This has left TTK Healthcare with unsold inventory worth ₹58.60 million. The company plans to explore remedies, including potential legal action, to mitigate the impact of this contract cancellation.